Application of sodium ferulate in preparing medicine to prevent and cure heptofibrosis

A technology of sodium ferulate and liver fibrosis, applied in the field of medicine

Inactive Publication Date: 2002-12-04
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, sodium ferulate is mainly used clinically for the prevention and treatment of cardiovascular and cerebrovascular diseases such as migraine, vascular headache, coronary heart disease, cerebrovascular disease, vasculitis, leukopenia and thrombocytopenia. A report on the use of Sodium Acid in the prevention and treatment of liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0004] Example 1 Inhibition of sodium ferulate on the proliferation and collagen synthesis of rat fat storage cell line HSC-T6

[0005] Get well-grown HSC-T6 cells and digest them with 0.25% trypsin to prepare a single cell suspension. Adjust the cell concentration to about 1.0×10 with DMEM conventional medium containing 10% calf serum 8 Pcs / L, seeded in 96-well culture plate, 100μL per well, placed in 5% CO at 37℃ 2 After 24 hours of incubation in the incubator, remove the culture solution and add 5 different concentrations of sodium ferulate of 28.9, 57.8, 115.6, 231.1, 462.6nmol / L as the drug group, and at the same time add the same amount without sodium ferulate The blank medium is used as the control group. Each concentration of the drug group and the control group has 3 multiple wells. After the addition, continue to incubate for 24 hours. Add 20μL of 5g / L Thiazole Blue (MTT) to each well for 4 hours. The optical density of each well sample at 490nm was measured with an enzy...

Embodiment 2

[0014] Example 2 Acute animal model test

[0015] 1. Animals: 70 Kunming mice, half male and half male, weight 22±2g.

[0016] 2. Animal grouping: Randomly divide the animals into 7 groups with 10 animals in each group. The first group is a normal animal control group, and the other groups are liver fibrosis model groups. Among them, the second, third, and fourth groups are carbon tetrachloride (CCl 4 ) Model group, which uses CCl 4 Causes liver fibrosis in mice; and the fifth, sixth, and seventh groups are D-galactosamine model groups, that is, D-galactosamine induces liver fibrosis in mice.

[0017] 3. Therapeutic drugs

[0018] (1) Bifendate, which is a traditional hepatoprotective drug, used as a therapeutic control drug.

[0019] (2) Sodium ferulate, as an experimental drug, observe its protective effect on acute liver injury in mice.

[0020] 4. Implementation plan

[0021] The first group is the normal control, the second and fifth groups are the model group controls, both ...

Embodiment 3

[0027] Example 3 Chronic animal model test

[0028] 1. Animals: 81 SD male rats, weighing about 180g.

[0029] 2. Animal grouping: randomly divide animals into 7 groups. 10 animals in the first group are the control group of normal animals, 16 animals in the second group are CCl 4 In the model control group, 11 animals in each of the 3rd, 4th, and 5th groups were the sodium ferulate prevention group, and 11 animals in the 6th and 7th groups were the sodium ferulate treatment group.

[0030] 3. Therapeutic drugs: Sodium ferulate, as an experimental drug, observe its effect on CCl 4 The effect of prevention and treatment of liver damage.

[0031] 4. Implementation plan

[0032] The first group is the normal control group, all of which were given saline by gavage at a dose of 10ml / kg.

[0033] Group 2 is CCl 4 Model control group.

[0034] The third group is the sodium ferulate low-dose prevention group, the dose is 50mg / kg.

[0035] The fourth group is the middle-dose prevention group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The application of sodium ferrulate in preparing medicines to prevent and cure heptofibrosis is disclosed. The said sodium ferulate is extracted from Chinese angelica root or Chuan-xiong rhizome. Experiments show that is has sure medical function to prevent and treat hepatofibrosis.

Description

Technical field: [0001] The invention relates to the technical field of medicine, and is a new application of sodium ferulate for preparing medicines for preventing and treating liver fibrosis. Background technique: [0002] Sodium ferulate is a water-soluble active ingredient extracted from Angelica sinensis or Ligusticum chuanxiong. It is also called Angelica sinensis or Ligusticum chuanxiong. It can be synthesized artificially. The chemical name is sodium 3-methoxy-4-hydroxy-phenylpropionate. Platelet aggregation, relieve vasospasm, analgesia, dilate coronary arteries, increase coronary flow, improve myocardial ischemia, enhance hematopoietic function and other pharmacological effects. At present, sodium ferulate is mainly used clinically for the prevention and treatment of cardiovascular and cerebrovascular diseases such as migraine, vascular headache, coronary heart disease, cerebrovascular disease, vasculitis, white blood cell and thrombocytopenia. It has been reported that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61P1/16
Inventor 胡晋红刘涛计一平李凤前
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap